Beta-Adrenergic gene therapy for cardiovascular disease by Eckhart, Andrea D & Koch, Walter J
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
Commentary
b b-Adrenergic gene therapy for cardiovascular disease
Andrea D Eckhart and Walter J Koch
Duke University Medical Center, Durham, North Carolina, USA
Abstract
Gene therapy using in vivo recombinant adenovirus-mediated gene transfer is an effective
technique that offers great potential to improve existing drug treatments for the complex
cardiovascular diseases of heart failure and vascular smooth muscle intimal hyperplasia.
Cardiac-specific adenovirus-mediated transfer of the carboxyl-terminus of the b-adrenergic
receptor kinase (bARKct), acting as a Gbg–b-adrenergic receptor kinase (bARK)1 inhibitor,
improves basal and agonist-induced cardiac performance in both normal and failing rabbit
hearts. In addition, bARKct adenovirus infection of vascular smooth muscle is capable of
significantly diminishing neointimal proliferation after angioplasty. Therefore, further
investigation is warranted to determine whether inhibition of bARK1 activity and
sequestration of Gbg via an adenovirus that encodes the bARKct transgene might be a useful
clinical tool for the treatment of cardiovascular pathologies.
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Introduction
Heart failure and hypertension are primary sources of mor-
bidity and mortality in developed countries. There are
numerous pharmaceutical agents on the market today that
are used to treat these complex diseases. However, such
agents are still not able to cure or to ameliorate symptoms
for all patients. For this reason, new drugs and therapies
are constantly being sought [1].
Gene therapy that uses in vivo recombinant adenovirus-
mediated gene transfer is a powerful technique that offers
great potential to improve existing drug treatments. It
allows for transient expression of gene products such as
peptides in targeted tissue, and therefore has the potential
to be a highly specific treatment. Adenovirus-mediated
gene therapy has recently come under assault because of
the potentially harmful inflammatory responses to the high
doses of adenovirus vectors [2]. It is likely that existing
vectors will need to be improved for successful applica-
tion in humans, although this is not a focus of the present
commentary and readers are referred to more recent
detailed discussions of viral vectors [2–5].
Gene therapy and cardiovascular disease
Several recent animal studies provide compelling
evidence that gene therapy will be of great benefit as aCurrent Controlled Trials in Cardiovascular Medicine    Vol 1 No 3 Eckhart and Koch
treatment for cardiovascular diseases. For example, gene
therapy using transgenes that enhance the contractile
function of the heart have the potential to act as a thera-
peutic bridge before and during cardiac transplantation.
Moreover, gene therapy may be able to ameliorate compli-
cations that arise throughout critical periods of cardiovas-
cular disease processes, such as the remodeling that
occurs after myocardial infarction or the restenosis that
can occur after angioplasty or stent implantation to correct
blocked arteries. Therapeutic agents aside, cardiovascular
gene transfer provides an invaluable tool for examining
disease-based mechanisms in animal models. Results of
studies from our laboratory and from others suggest that
gene therapy could become a very powerful therapeutic
strategy in the very near future.
Delivery of transgene
One hurdle that must be overcome in order for gene
therapy to become successful in humans is a clinically rel-
evant, reliable, and specific method of delivery of the
transgene to the cardiovascular system. Several groups
have demonstrated the feasibility of delivering transgenes
to the heart via direct intramyocardial injection [6,7], ex
vivo perfusion [8–10], and finally an intracoronary
approach [11–14]. Direct injection of the adenovirus into
the ventricular wall has been shown to induce significant
expression of transgenes with a limited amount of adeno-
virus [6,7]. However, there is needle damage and expres-
sion is limited to the site of injection.
Although limited in scope, ex vivo delivery systems, such
as during cardiac transplantation, are clinically relevant
and allow for global expression of different transgenes
[8–10]. In order to accomplish expression of the trans-
gene, the aortic root of the donor heart is perfused with
adenoviral solution and then heterotopically transplanted
into the recipient [9]. This method has been used to target
robust myocardial overexpression of b2-adrenergic recep-
tors (b2ARs), which translated into a functional effect on
the transplanted heart in the form of significantly enhanced
basal and agonist-induced contractility [10]. Expression of
the b2AR transgene was transient, and peak expression
was seen at 5 days and returned to baseline levels after
14 days [9]. This method may provide a unique opportu-
nity for genetic manipulation of the donor organ, poten-
tially enhancing its function during the stresses of
open-heart surgery. In addition, because gene delivery is
carried out in the donor heart, total body adenovirus expo-
sure is limited in the recipient, thus making it clinically
attractive for the vectors that are now available.
Another successful method of gene transfer to the heart is
injection of adenovirus through the coronary arteries.
Recently, investigators from two laboratories, including
ours, have developed a method for global myocardial
transgene delivery [12,13]. This method involves injecting
adenovirus into the left ventricular cavity while the aorta or
aorta and pulmonary artery are cross-clamped for several
seconds, allowing perfusion of the coronary arteries via
the aortic root. We have shown that in vivo myocardial
gene delivery in rabbits using this left ventricular/cross-
clamp delivery method of either the b2AR transgene or a
gene that encodes a peptide inhibitor of the bARKct can
enhance cardiac function in normal hearts as well as
failing hearts [13,15]. The bARKct is comprised of the last
194 amino acids of bovine bARK1, which contains the
region for binding to Gbg (Gbg-subunits of activated hetero-
trimeric G proteins), a process that is required for bARK1
activation [15]. Thus, the bARKct inhibits the activity of
bARK1 through the competitive binding of Gbg. Global in
vivo myocardial gene delivery via this left ventricular/aortic
cross-clamp technique has been quite successful. It is
quite invasive, however, because it requires thoracotomy;
thus, less invasive methods are desirable.
Recently, it has become possible to deliver therapeutic
adenoviral transgenes to the beating rabbit heart in vivo
via a percutaneous intracoronary catheterization injection
[14]. This technique supports transgene delivery to the
area of the heart that is supplied by the catheterized
artery, and may be advantageous when global transgene
delivery is not required. This percutaneous coronary
catheterization technique does not require entrance in the
thoracic cavity, and is therefore an attractive and clinically
relevant technique for use in heart failure treatment. We
delivered the b2AR transgene in a ventricular-specific
manner after right coronary artery or left circumflex coro-
nary artery catheterization and adenovirus injection, and
found that in vivo ventricular contractility can be enhanced
5 days after this gene treatment [14].
b b-Adrenergic receptor signaling and heart
failure
The use of bAR signaling components as gene therapy for
heart failure has been the subject of debate for the past
couple of years [16]. It is clear that alterations in the
myocardial  bAR system both precede and accompany the
development of heart failure in humans [17,18]. These
alterations include a 50% decrease in b1ARs, and func-
tional uncoupling of remaining b1ARs and b2ARs in the
myocardium. The latter is probably mediated by a signifi-
cant upregulation in the expression and activity of bARK1
[19]. Importantly, previous work in our laboratory using
novel genetically engineered mice has clearly shown that
enhancing  bAR signaling through overexpression of
b2ARs or inhibiting bARK1 via the bARKct are novel thera-
peutic approaches to enhance the function of the heart
[20]. In fact, this strategy has prevented the development
of cardiomyopathy in murine models of heart failure [20].
Thus, data in transgenic mice coupled with our initial gene
therapy results in rabbits demonstrate that enhancing
myocardial  b-adrenergic signaling either by overexpressingc
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b2ARs or by inhibiting bARK1 activity may provide novel
molecular ventricular assistance for failing hearts.
b b-Adrenergic receptor signaling and vascular
intimal proliferation
Not only has gene therapy with bAR signaling compo-
nents been successful for treating animal models of heart
failure, but we have also shown that it can be used suc-
cessfully for vascular pathologies as well [21,22]. Func-
tional expression of transgenes including the b2AR in
vascular smooth muscle has been demonstrated using
catheter-mediated adenovirus delivery to de-endothelial-
ized rat carotid arteries [22]. Total bAR density was
increased in the carotids after b2AR adenovirus treatment,
and this resulted in an enhancement in isoproterenol-
induced vasorelaxation [22]. In humans, this could be
used to improve blood flow specifically to ischemic
regions, and may also lead to novel therapeutic strategies
for treatment of hypertension.
Percutaneous transluminal coronary angioplasty is a
method that is employed to improve cardiac blood flow
through compromised vessels in a number of diseases,
including unstable angina and myocardial infarction [23].
However, at the site of angioplasty there is significant
injury to the arterial wall, and a major limitation to this tech-
nique is induction of the accumulation and proliferation of
vascular smooth muscle cells from the tunica media to the
tunica intima of the arterial wall. This proliferation leads to
restenosis in 30–60% of cases within 3–6 months and is
a clinical process known as intimal hyperplasia [24].
Because adenovirus-mediated transfer of a functional
gene to vascular smooth muscle is feasible, we have been
interested in determining whether we could prevent the
smooth muscle intimal hyperplasia by directing transgene
expression at the site of injury. Interestingly, it appears
that, for several mitogenic agents that signal through G-
protein-coupled receptors, Gbg is a critical signaling com-
ponent for mitogenesis and cell proliferation. However,
this has never been documented for in vivo vascular
smooth muscle intimal hyperplasia. Thus, we have utilized
the bARKct transgene as an inhibitor of Gbg in a rat carotid
balloon-catheter angioplasty injury model in order to inves-
tigate the role of Gbg in this pathologic event [21]. As
detailed above, because the bARKct inhibits bARK activity
through competitive Gbg binding, it serves as a specific
Gbg inhibitor. Importantly, we found that Gbg plays a major
role in vascular smooth muscle proliferation, because tar-
geted inhibition of Gbg by the bARKct resulted in a signifi-
cant reduction in intimal hyperplasia in this rat model of
arterial restenosis [21].
Conclusion
Experimental data strongly suggest a key role for the bAR
signaling system in the pathogenesis of cardiovascular
disease. In heart failure, increasing bAR signaling through
genetic inhibition of bARK1 or overexpression of b2AR
improves cardiac performance by providing molecular ven-
tricular assistance, and may represent a novel therapeutic
approach to the management of heart failure. In addition,
smooth muscle intimal hyperplasia is prevented with the
expression of bARKct. Therefore, vascular pathologies are
also dependent on G-protein-coupled receptor signaling.
Work from our laboratory and from others suggests that
adenovirus-mediated gene therapy is a powerful technique
for the selective, tissue-specific expression of gene prod-
ucts in the cardiovascular system. To date, pharmaceutical
agents are able to achieve this, and current management
of both heart failure and intimal hyperplasia is not capable
of preventing or completely alleviating symptoms and mor-
tality. Therefore, we remain optimistic that adenovirus-
mediated gene therapy and, more specifically, the
inhibition of bARK1 activity and sequestration of Gbg via
the bARKct will be an invaluable clinical tool for the treat-
ment of cardiovascular pathologies.
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